357 results about "Abnormal expression" patented technology

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and / or ameliorating diseases and disorders associated with aberrant expression and / or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.

PROBLEMThere are provided induced malignant stem cells capable of in vitro proliferation that are useful in cancer research and drug discovery for cancer therapy, as well as processes for production thereof, cancer cells derived from these cells, and applications of these cells.MEANS FOR SOLVINGAn induced malignant stem cell capable of in vitro proliferation are characterized by satisfying the following two requirements:(1) having at least one aberration selected from among (a) an aberration of methylation (high or low degree of methylation) in a tumor suppressor gene or a cancer-related genetic region in endogenous genomic DNA, (b) a somatic mutation of a tumor suppressor gene or a somatic mutation of an endogenous cancer-related gene in endogenous genomic DNA, (c) abnormal expression (increased or reduced / lost expression) of an endogenous oncogene or an endogenous tumor suppressor gene, (d) abnormal expression (increased or reduced / lost expression) of a noncoding RNA such as an endogenous cancer-related microRNA, (e) abnormal expression of an endogenous cancer-related protein, (f) an aberration of endogenous cancer-related metabolism (hypermetabolism or hypometabolism), (g) an aberration of endogenous cancer-related sugar chain, (h) an aberration of copy number variations in endogenous genomic DNA, and (i) instability of microsatellites in endogenous genomic DNA in an induced malignant stem cell; and(2) expressing genes including POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

Compositions and methods for diagnosing, treating and / or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and / or monitoring liver cancers using the expressing of CDH17 involve detecting and / or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor.

The invention discloses an anti-human Tim-3 neutralized monoclonal antibody L3D and an application thereof. Antibody light and heavy chain variable region genes are cloned from a prepared anti-human Tim-3 neutralized monoclonal antibody L3D hybridoma cell; and the obtained light chain and heavy chain variable region genes can be used for encoding a monoclonal antibody variable region. Based on the light and heavy chain variable region genes of the monoclonal antibody, a plurality of small molecular genetic engineering antibodies can be constructed and expressed. Polypeptides or proteins encoded on the basis of the genes can be cross-linked with a plurality of bioactive molecules, so that a Tim-3 expression level detection reagent is prepared for diagnosing and treating diseases caused by abnormal expression of Tim-3.

The invention discloses a thieno 2,4-substituted pyrimidine compound of which the general formulas are (I), (II), (III) and (IV), or pharmaceutically acceptable salt or stereisomer or a prodrug molecule, and a pharmaceutical composition and application thereof. The thieno 2,4-substituted pyrimidine compound can effectively restrain abnormal expression of Aurora kinase, has specific inhibited effect on Aurora-A and Aurora-B, can be applied to a novel field of molecular targeting treatment, and has strong inhibitory activity on an excessive hyperplasia disease, especially cervical tumor cells, human macrophage line leukemia cell, and human t-lymphocyte line cancer cell.

The invention discloses a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 system capable of simultaneously knocking out KRAS genes and EGFR genes. The system comprises sgRNA for specifically targeting KRAS genes and sgRNA for specifically targeting EGFR genes, wherein a corresponding DNA sequence of the sgRNA for specifically targeting KRAS genes is shown as SEQ ID NO.1 or / and SEQ ID NO.2; and a corresponding DNA sequence of the sgRNA for specifically targeting EGFR genes is shown as SEQ ID NO.11 or / and SEQ ID NO.12. The invention further discloses application of the system in preparation of medicines for treating cancers. The CRISPR-Cas9 system disclosed by the invention is capable of simultaneously and efficiently knocking out two cancer driving factors KRAS and EGFR which are highly-expressed in lung cancer. The system is simple in operation and high in knockout efficiency and is expected to be applied to treatment of the lung cancer. The system disclosed by the invention is applicable to multiple cancers with abnormal expressions of the EGFR and KRAS.

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin alphaVbeta3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin alphaVbeta3, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and / or activity of integrin alphaVbeta3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the HMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.

The invention discloses a CRISPR-Cas9 system for knocking out the gene GRIN2D and its application. The CRISPR-Cas9 system comprises Cas9 and gRNA specifically targeting to the gene GRIN2D. The invention also discloses application of the CRISPR-Cas9 system to preparation of drugs used for treating cancer and application of the gene GRIN2D to diagnostic kits and medicines used for precise treatmentof stomach cancer and other tumors. In virtue of a clinical sample tissue chip of stomach cancer, the gene GRIN2D is proved to be increased in expression in stomach cancer tissue and be related to prognosis according to immunohistochemical results. The CRISPR-Cas9 system provided by the invention can highly efficiently knock out the highly-expressed gene GRIN2D in stomach cancer and inhibit the proliferation and migration / invasion of gastric cancer cells, and is simple to operate and high in knockout efficiency. The CRISPR-Cas9 system is expected to be applied to diagnosis and treatment of stomach cancer and other tumors with over-expressed GRIN2D. The CRISPR-Cas9 system is applicable to a plurality of tumors with abnormal expression of GRIN2D.

The present invention provides a method for diagnosing a disease or disorder associated with aberrant GSK-3β expression and / or activity or for determining the predisposition of a subject to the disease or disorder. In particular, the methods of the present invention comprise detecting a marker that comprises one or more polymorphisms and / or one or more allelic variants of a glycogen synthase kinase 3β gene. The present invention also relates to a method for identifying new markers that are diagnostic of a disease or disorder associated with aberrant GSK-3β expression and / or activity. Furthermore, the present invention relates to methods of identifying and producing candidate compounds for the treatment of a disease or disorder associated with aberrant GSK-3β expression and / or activity.

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.

Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and / or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.

The invention discloses a substituted3-indole Bcl-2 protein inhibitor and a preparation method and an application thereof. The compound has a structure as shown in the general formula I or II. The compound of the invention has a strong inhibitory activity to Bcl-2 protein and can prevent or treat related mammalian diseases caused by abnormal expression of Bcl-2 protein. The invention also relates to a pharmaceutical application of a compound of the compound having the structure as shown in the general formula I or II.

The invention discloses a substituted purin-9-acetamino isohydroxamic acid histone deacetylase inhibitor and a preparation method and application thereof. The inhibitor has the structure as shown in formula I described in the specification. The inhibitor disclosed by invention has strong inhibitory activity on HDAC (histone deacetylase) and can be used for the prevention or treatment of related mammalian diseases caused by abnormal expression of histone deacetylase. The invention also relates to an application of the inhibitor having the general formula I in preparing the medicines.

Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and / or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

The invention provides human protein modification and maintenance molecules (PMMM) and polynucleotides which identify and encode PMMM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PMMM.

The invention provides nine micro RNA (Ribonucleic Acid) (miRNA) molecular markers for diagnosing rheumatoid arthritis and an application thereof to a detection kit. The miRNA molecular markers have abnormal expression in blood of patients with the rheumatoid arthritis to diagnose the rheumatoid arthritis; the miRNA molecular marker has high combination sensitivity and specificity; materials are convenient to fetch; the miRNA molecular marker is safe and noninvasive and provides important evidences to early diagnosis of diseases and disease course monitoring. The invention further provides a kit for diagnosing the rheumatoid arthritis and the application of the miRNA molecular marker to the diagnosing kit. The kit is characterized by comprising the combination of the nine miRNA molecular markers for detecting blood plasma and a reagent for detecting the nine miRNA molecular markers.

The invention discloses an elevator security and protection control system based on load states. The system comprises an elevator car and an abnormality monitoring system, wherein the elevator car isprovided with a guide rail, a first camera and a second camera; the first camera is used for daily monitoring; the second camera slides along the guide rail to monitor abnormalities of the elevator car; the abnormality monitoring system comprises a vibration inductor, an infrared emitter, an infrared receiver and a remote monitor; when the vibration exceeds a preset maximum threshold, the vibration inductor sends a starting signal to the second camera, and frames are displayed on the remote monitor; when an elevator door is opened and the signal is not interrupted, the infrared receiver controls startup of the second camera; a face recognition module of a security and protection system obtains face images from frames shot by the second camera to send to an expression analysis module; and the expression analysis module analyzes abnormal expressions and sends alarm signals to an alarm module. The system can effectively prevent such events as robbing, seizing and violence attacking in elevators, and guarantees personal safety of users during taking of the elevators.

The present invention addresses the problem of providing malignant stem cells that can be grown in vitro and are useful in cancer therapy research and drug discovery research for cancer therapy, a method for producing same, cancer cells induced from the cells, and use for the cells. Provided are induced malignant stem cells that can be grown in vitro, the induced malignant stem cells being characterized in (1) having at least one type of abnormality selected from among (a) abnormal methylation (hypermethylation or hypomethylation) of a cancer suppressor gene or cancer-related gene region in the endogenous genome DNA, (b) somatic mutation of a cancer suppressor gene in the endogenous genome DNA or somatic mutation of an endogenous cancer-related gene, (c) abnormal expression (increased expression or decreased / lost expression); of an endogenous cancer gene or endogenous cancer suppressor gene, (d) abnormal expression (increased expression or decreased / lost expression) of non-coding RNA such as endogenous cancer-related micro RNA, (e) abnormal expression (increased expression or decreased / lost expression) of an endogenous cancer-related protein, (f) endogenous cancer-related metabolism abnormality (hypermetabolism or hypometabolism), or (g) abnormal endogenous cancer-related carbohydrate; and (2) expressing the POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

The invention discloses a multi-feature fusion driver abnormal expression recognition method. The multi-feature fusion driver abnormal expression recognition method comprises the steps: S1, tracking and monitoring expression actions of a driver in real time through a camera installed on the driver side; S2, precisely identifying expression details in the real-time driver video; S3, detecting the positions of the eyes, and judging whether the eyes are tired or not; S4, positioning the edge contour of the mouth, and judging whether yawn action occurs or not; S5, detecting a head action, and judging whether fatigue occurs or not; S6, weighting the detection results of the eye state, the mouth state and the head motion state, finally judging whether fatigue occurs or not, and outputting the detection results; and S7, combining the identification result of the current frame as an estimated position of subsequent frame identification, and respectively detecting actions in subsequent frames to realize continuous detection and identification of abnormal behaviors of the driver. According to the invention, real-time monitoring and alarm triggering can be carried out, a driver is warned andreminded, and traffic accidents are prevented, and the safety in the driving process is ensured.

The invention discloses an identity identification system and a method based on image and somatosensory analysis. The system comprises a data acquisition module, a data analysis center and a security dispatching center connected in sequence, wherein the data acquisition module is used for acquiring face images and body actions in a security area; the data analysis center is used for analyzing the face images, expressions and the body actions; and the security dispatching center is used for carrying out security dispatching according to a result obtained through analysis of the data analysis center. According to the identity identification system and the method based on image and somatosensory analysis, whether a person in the security area enters illegally is judged through the face image, and security dispatching measures are taken; expression analysis is carried out on a legally-entering person; and when an abnormal expression is analyzed and obtained, a body action is further analyzed, and a more accurate basis is provided for judgment of hidden safety dangers.

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin alphavbeta3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin alphavbeta3, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and / or activity of integrin alphavbeta3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

The invention discloses a method for detection of microRNAs in excreta (sputum, faeces and urine) as a biomarker for early screening and diagnosing lung cancer, colorectal cancer and bladder cancer. The method comprises: (1) screening abnormal expression microRNAs existed in tissues of the lung cancer, the colorectal cancer and the bladder cancer; (2) by using resection tumor samples from patients of the lung cancer, the colorectal cancer and the bladder cancer, verifying the screened microRNAs in the tumor tissues; and (3) detecting expressions of the microRNAs in samples of sputum, faeces and urine from the patients of the lung cancer, the colorectal cancer and the bladder cancer, analyzing correlation with expression in the tissues, and confirming the microRNAs for early screening and diagnosis. The method is substantially characterized in that the microRNAs in the excreta is taken as the biomarker for early screening and diagnosing the cancers, and the method helps to realize noninvasive screening for the cancer patients and possesses a wide application scope.

The invention relates to a human reforming mouse ING4 (tumor growth inhibition factor) gene and recombinant adenovirus (adenovirus hominis 5 shape Ad-ING4-DeltaGFP), wherein preservation cooperation is Chinese typical culture preservation centre, preservation number is CCTCC-V200701. The invention also relates to a human reforming gene mutation technique, adenovirus transition carrier removing GFP and homologous recombinant adenovirus carrier. The ING4 gene and recombinant adenovirus carrier provide new immunodiagnosis and target therapeutic approach for treating neoplastic disease, development disease, immune disease, the other disease owing to abnormal expression of tumour growth inhibition factor ING4, special cancer of the lungs and leukocythemia, which is provided with a giant application prospect.

The applicant provides a long-chain non-coding lncRNA-OD1 which is formed by transcribing a gene located at a chromosome 18: chr18: 77343316-77345492, hg19, and the length of the gene sequence is 2177bp. The applicant also provides application of the long-chain non-coding lncRNA-OD1 in preparation of a reagent, a kit or a gene chip for predicting osteoporosis. In the invention, through a gene chip technology, a bioinformatics technology and a molecular biological technology, whether abnormal expression occurs in an LncRNA in an osteoporosis process can be determined, and the function of the LncRNA in the pathogenetic process of osteoporosis is understood, so that a new clue is provided for early diagnosis of osteoporosis, and a molecular mechanism of occurrence of osteoporosis is enriched favorably.